Skip to main content

Advertisement

Table 2 Clinical and pathologic prognostic factors in the clinical cohorts

From: The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence

  CCIH CCF RPCI
  Univariate HR Factor Bivariate HR TRMT2A Bivariate HR Univariate HR Factor Bivariate HR TRMT2A Bivariate HR Univariate HR Factor Bivariate HR TRMT2A Bivariate HR
ER 0.435 (0.11) 1.05 (0.93) 7.15 (0.0012) 0.293 (0.014) 0.233 (0.044) 1.415 (0.63) 0.471 (0.13) 0.573 (0.3) 2.573 (0.066)
PR 0.347 (0.16) 1.04 (0.97) 7.08 (0.0024) 0.205 (0.036) 0.143 (0.066) 2.703 (0.082) 0.18 (0.1) 0 (0.73) 2.8 (0.058)
Age 1.01 (0.52) 1.01 (0.61) 6.91 (0.00035) 0.982 (0.29) 0.974 (0.15) 3.457 (0.02) 1 (0.87) 1 (0.85) 3.39 (0.013)
N Stage 4.16 (0.00043) 3.9 (0.0027) 5.63 (0.0015) 2.47 (0.0001) 2.41 (0.0002) 2.03 (0.23) 1.17 (0.52) 1.37 (0.3) 3.33 (0.014)
T Stage 1.2 (0.54) 1.07 (0.85) 6.93 (0.00046) 2.34 (0.0001) 2.72 (0.0001) 2.31 (0.13) 1.24 (0.26) 1.14 (0.56) 3.35 (0.014)
Grade 0.869 (0.74) 0.805 (0.59) 12.25 (0.00018) 2.16 (0.079) 2.35 (0.092) 2.79 (0.058) 3.5 (0.018) 2.96 (0.077) 3.34 (0.017)
Chemo 1.64 (0.36) 0.925 (0.89) 7.14 (0.0005) 8.78 (0.0048) 15.13 (0.0098) 2.23 (0.17) 1.46 (0.42) 1 (0.99) 3.34 (0.014)
  1. Hazard ratios (p-values) of common prognostic factors within the Her2+ patients in each of the three cohorts. The first column reports each factor as univariate HR's whereas the second and third column reports each factor and TRMT2A respectively as bivariate HR's.